Insights from 2025 ASCO® GI Annual Meeting
Video Player is loading.
10 seconds
Playback speed
ASCO® GI 2025 Summary: Meta-Analysis of Phase II/III RCTs to Evaluate the Incidence of HTN, Proteinuria, Hemorrhage, and VTE in GI Cancer Patients Treated With Fruquintinib
By
Insights from 2025 ASCO® GI Annual Meeting
FEATURING
Kyaw Thein
By
Insights from 2025 ASCO® GI Annual Meeting
FEATURING
Kyaw Thein
Comments 0
Login to view comments.
Click here to Login
